BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Dicerna Pharmaceuticals 

480 Arsenal Street
Building 1, Suite 120
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-621-8097 Fax: n/a


SEARCH JOBS





Segment
Start Up





 Company News
Dicerna (DRNA) Announces Pricing Of Follow-On Offering Of Common Stock 5/21/2015 11:56:24 AM
Dicerna (DRNA) Announces Follow-On Public Offering Of Common Stock 5/19/2015 1:15:49 PM
Dicerna (DRNA) To Present Interim Clinical Data From First DCR-MYC Phase 1 Study In Patients With Advanced Solid Tumors At The 2015 ASCO Annual Meeting 5/14/2015 12:18:49 PM
Dicerna (DRNA) Announces Expansion Of Ongoing DCR-MYC Phase 1 Study To Evaluate Safety And Efficacy In Patients With Advanced Pancreatic Neuroendocrine Tumors (PNETs) 5/14/2015 10:45:26 AM
Dicerna (DRNA) Announces First Quarter 2015 Financial And Operational Results 5/12/2015 10:51:20 AM
Dicerna (DRNA) Announces Potent, Durable Knockdown Of Gene Expression In Non-Human Primates With DsiRNA-EX Conjugates Being Investigated For Treatment Of Primary Hyperoxaluria Type 1 (PH1) 5/6/2015 9:42:53 AM
Dicerna (DRNA) To Present At The 17th Annual TIDES: Oligonucleotide And Peptide Therapeutics From Research Through Commercialization Conference 5/4/2015 8:34:46 AM
Dicerna (DRNA) To Announce First Quarter 2015 Financial Results And Host Conference Call On May 11, 2015 4/30/2015 12:26:49 PM
FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna (DRNA)’s Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1) 4/23/2015 8:21:58 PM
Dicerna (DRNA) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 4/1/2015 3:34:17 PM
12345678910